Fundraising Overview - The company, Jiangsu Jicui Yaokang Biotechnology Co., Ltd., has been approved to publicly issue 50 million shares at a price of RMB 10.03979 million, resulting in a net fundraising amount of RMB 1,026.1021 million after deducting issuance costs [1][2] - The funds have been fully received and verified by the accounting firm, with a verification report issued on April 19, 2022 [1] Fund Management and Regulatory Compliance - The company has established a special account for the management of the raised funds and signed a regulatory agreement with the sponsor, Huatai United Securities Co., Ltd., and the bank managing the special account [2][3] - A board meeting and a shareholder meeting were held to approve the allocation of RMB 200 million for a new project focused on "AI-driven organ and animal disease model multimodal preclinical drug research platform" [2][3] Special Account and Agreement Details - The special account has been opened at China Merchants Bank, Nanjing Branch, specifically for the new project [3] - The agreement stipulates that the funds in the special account must only be used for the designated project and outlines the responsibilities of all parties involved, including the sponsor's oversight role [4][5] Oversight and Reporting - The sponsor is required to monitor the use of the funds and conduct semi-annual checks on the account [4][5] - The bank must provide monthly account statements to both the company and the sponsor, ensuring transparency in fund management [5] Agreement Validity and Termination - The agreement will remain in effect until all funds are fully utilized and the account is closed, with provisions for termination in case of non-compliance [6]

Group 1 - The company plans to use up to RMB 700 million of its idle funds for entrusted wealth management, effective from the board's approval date until the next annual board meeting [1][10][52] - The purpose of the entrusted wealth management is to improve the efficiency of idle funds and increase investment returns for the company and its shareholders [2][9] - The funds for this investment will come from temporarily idle self-owned funds, ensuring that the company's normal operations are not affected [3][4] Group 2 - The investment products will primarily include low-risk, high-security financial products, such as fixed-income products and securities, and will not involve stock investments [4][5] - The board has authorized the management to make investment decisions and sign relevant legal documents, with the finance and funding departments responsible for implementation [5][6] - The company will disclose information regarding the purchase of wealth management products in accordance with the regulations of the Shanghai Stock Exchange [6] Group 3 - The company has also approved changes to certain fundraising projects, including adjustments to investment amounts and project timelines, as well as the addition of new projects [18][19][45] - The project "Mode Animal Mouse R&D Breeding Integrated Base Construction" will have its investment amount reduced from RMB 611.13 million to RMB 430.26 million, and the expected completion date will be extended to April 2030 [21][45] - A new project, "AI-driven Organoid and Animal Disease Model Multi-modal Preclinical Drug Research Platform," with an investment of RMB 200 million, has been introduced to enhance the company's R&D capabilities [24][45]